Document Detail

Activation of P53 in HepG2 cells as surrogate to detect mutagens and promutagens in vitro.
MedLine Citation:
PMID:  20655369     Owner:  NLM     Status:  MEDLINE    
The current genotoxicity tests of the standard in vitro battery, especially those using mammalian cells, are limited by their low specificity and highlight the importance of new in vitro tools. This study aimed to evaluate the suitability of HepG2 cells for assaying mutagens and promutagens. We determined P53 activity as surrogate genotoxicity endpoint in HepG2 cells. Our results revealed a significant P53-induction by actinomycin D, methyl methanesulfonate and etoposide. Prior to the investigation of promutagens we characterized HepG2 cells by analyzing the expression of 45 genes involved in xenobiotic metabolism and measuring the activity of selected Cytochrome-P450 (CYP) enzymes. We determined a limited metabolic capacity prompting us to employ a co-treatment with rat liver S9 as metabolic activation system (MAS) for promutagens. While cyclophosphamide showed an elevation of activated P53 in the presence of S9, 7,12-dimethylbenz[a]anthracene and aflatoxin B(1) responded without the MAS. Inhibition of cellular CYP3A4 or CYP1A/1B suppressed the aflatoxin B(1)- and dimethylbenz[a]anthracene-mediated P53 response, respectively, indicating that HepG2 cells are capable of metabolizing these compounds in a CYP1A/B/3A4-dependent manner. In summary, our results indicate that P53 activation in HepG2 cells combined with a MAS can be used for the identification of new (pro)genotoxicants.
Kathleen Boehme; Yasmin Dietz; Philip Hewitt; Stefan O Mueller
Related Documents :
20550649 - The new platinum(iv) derivative la-12 shows stronger inhibitory effect on hsp90 functio...
19946469 - Alterations in gene expression and sensitivity to genotoxic stress following hdmx or hd...
8547219 - Inhibition of human glioblastoma cell growth by waf1/cip1 can be attenuated by mutant p53.
21389099 - Internalization of oncolytic reovirus by human dendritic cell carriers protects the vir...
11796579 - P53-independent expression of p21(cip1/waf1) in plasmacytic cells during g(2) cell cycl...
11306489 - The proteasome inhibitor ps-341 inhibits growth, induces apoptosis, and overcomes drug ...
7632459 - Phagocytosis of individual cd4+ t cells by hiv-induced t cell syncytia.
6451199 - Abnormalities of immunoregulation in progressive systemic sclerosis. evidence for exces...
25423019 - Live-cell mass profiling: an emerging approach in quantitative biophysics.
Publication Detail:
Type:  Journal Article     Date:  2010-07-22
Journal Detail:
Title:  Toxicology letters     Volume:  198     ISSN:  1879-3169     ISO Abbreviation:  Toxicol. Lett.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-08-24     Completed Date:  2010-09-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7709027     Medline TA:  Toxicol Lett     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  272-81     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
Merck KGaA, Merck Serono, Toxicology, 64293 Darmstadt, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / metabolism
Cell Survival / drug effects
Cytochrome P-450 CYP1A1 / antagonists & inhibitors,  biosynthesis,  genetics
Cytochrome P-450 CYP3A / antagonists & inhibitors,  biosynthesis,  genetics
DNA Damage*
Gene Expression Profiling
Hep G2 Cells
Metabolic Detoxication, Drug / genetics
Mutagenicity Tests / methods
Mutagens / toxicity*
Tumor Suppressor Protein p53 / metabolism*
Reg. No./Substance:
0/Biological Markers; 0/Mutagens; 0/Tumor Suppressor Protein p53; EC protein, human; EC P-450 CYP1A1; EC P-450 CYP3A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mechanisms of genetically-based resistance to malaria.
Next Document:  Effect of medium-chain triglycerides on the release behavior of Endostar encapsulated PLGA microsphe...